Skip to main content
Top
Published in: AIDS Research and Therapy 1/2024

Open Access 01-12-2024 | Human Immunodeficiency Virus | Research

Characterization of intestinal fungal community diversity in people living with HIV/AIDS (PLWHA)

Authors: Pengfei Meng, Guichun Zhang, Xiuxia Ma, Xue Ding, Xiyuan Song, Shuyuan Dang, Ruihan Yang, Liran Xu

Published in: AIDS Research and Therapy | Issue 1/2024

Login to get access

Abstract

Acquired Immune Deficiency Syndrome (AIDS) is a highly dangerous infectious disease caused by the Human Immunodeficiency Virus (HIV), a virus that attacks the human immune system. To explore the correlation between intestinal fungal community and immune function (Immune cells and inflammatory factors) in people living with HIV/AIDS (PLWHA). The feces and blood samples were collected from two groups of subjects: PLWHA and healthy controls. High-throughput sequencing of the internal transcribed spacer 1, flow cytometry, and ELISA were performed to analyze the differences and correlations between fungal microbiota, cellular immune status and serum inflammatory factors in the two groups. There were significant differences in the composition of fungal microbiota between the two groups. The relative abundance of Candida, Bjerkandera, and Xeromyces in PLWHA was significantly higher than that of healthy volunteers (P < 0.01), while the relative abundance of Mycospaerella, Xeroxysium, Penicillium, and Glomerella in PLWHA was significantly lower than that of healthy volunteers. The correlation analysis results show that Mycospaerella and Xeromyces are significantly positively correlated with CD4+/CD8+ T cells and the anti-inflammatory cytokine IL-4. On the other hand, Candida was positively correlated with pro-inflammatory factors negatively correlated with CD4+/CD8+ T cells and the anti-inflammatory cytokine IL-4, while it is positively correlated with pro-inflammatory cytokines. The significant increase in the relative abundance of Candida may be one of the important causes of intestinal damage in PLWHA. The results of this study contribute to the understanding of the relationship between fungal microbiota structure and immune function in the gut ecology of PLWHA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S. HIV virology and pathogenetic mechanisms of Infection: a brief overview. Annali dell’Istituto Superiore Di Sanita. 2010;46(1):5–14.PubMed Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S. HIV virology and pathogenetic mechanisms of Infection: a brief overview. Annali dell’Istituto Superiore Di Sanita. 2010;46(1):5–14.PubMed
3.
go back to reference Akiyama H, Gummuluru S. HIV-1 persistence and chronic induction of Innate Immune responses in macrophages. Viruses. 2020;12(7). Akiyama H, Gummuluru S. HIV-1 persistence and chronic induction of Innate Immune responses in macrophages. Viruses. 2020;12(7).
4.
go back to reference Zilberman-Schapira G, Zmora N, Itav S, Bashiardes S, Elinav H, Elinav E. The gut microbiome in human immunodeficiency virus Infection. BMC Med. 2016;14(1):83.PubMedPubMedCentralCrossRef Zilberman-Schapira G, Zmora N, Itav S, Bashiardes S, Elinav H, Elinav E. The gut microbiome in human immunodeficiency virus Infection. BMC Med. 2016;14(1):83.PubMedPubMedCentralCrossRef
5.
go back to reference Anastasi JK, Capili B. HIV-related diarrhea and outcome measures. J Association Nurses AIDS Care: JANAC. 2001;12 Suppl:44–50. quiz 1–4. Anastasi JK, Capili B. HIV-related diarrhea and outcome measures. J Association Nurses AIDS Care: JANAC. 2001;12 Suppl:44–50. quiz 1–4.
6.
go back to reference Steele AK, Lee EJ, Vestal B, Hecht D, Dong Z, Rapaport E, et al. Contribution of intestinal barrier damage, microbial translocation and HIV-1 Infection status to an inflammaging signature. PLoS ONE. 2014;9(5):e97171.PubMedPubMedCentralCrossRefADS Steele AK, Lee EJ, Vestal B, Hecht D, Dong Z, Rapaport E, et al. Contribution of intestinal barrier damage, microbial translocation and HIV-1 Infection status to an inflammaging signature. PLoS ONE. 2014;9(5):e97171.PubMedPubMedCentralCrossRefADS
7.
go back to reference El Kamari V, Sattar A, McComsey GA. Brief Report: Gut Structural Damage: an Ongoing Process in Chronically Untreated HIV Infection. Journal of acquired immune deficiency syndromes (1999). 2019;80(2):242-5. El Kamari V, Sattar A, McComsey GA. Brief Report: Gut Structural Damage: an Ongoing Process in Chronically Untreated HIV Infection. Journal of acquired immune deficiency syndromes (1999). 2019;80(2):242-5.
8.
go back to reference Tinmouth J, Kandel G, Tomlinson G, Walmsley S, Steinhart HA, Glazier R. Systematic review of strategies to measure HIV-related diarrhea. HIV Clin Trial. 2007;8(3):155–63.CrossRef Tinmouth J, Kandel G, Tomlinson G, Walmsley S, Steinhart HA, Glazier R. Systematic review of strategies to measure HIV-related diarrhea. HIV Clin Trial. 2007;8(3):155–63.CrossRef
9.
go back to reference Schmidt TSB, Raes J, Bork P. The human gut Microbiome: from Association to Modulation. Cell. 2018;172(6):1198–215.PubMedCrossRef Schmidt TSB, Raes J, Bork P. The human gut Microbiome: from Association to Modulation. Cell. 2018;172(6):1198–215.PubMedCrossRef
10.
go back to reference Gomaa EZ. Human gut microbiota/microbiome in health and Diseases: a review. Antonie Van Leeuwenhoek. 2020;113(12):2019–40.PubMedCrossRef Gomaa EZ. Human gut microbiota/microbiome in health and Diseases: a review. Antonie Van Leeuwenhoek. 2020;113(12):2019–40.PubMedCrossRef
11.
go back to reference Kim SK, Guevarra RB, Kim YT, Kwon J, Kim H, Cho JH, et al. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J Microbiol Biotechnol. 2019;29(9):1335–40.PubMedCrossRef Kim SK, Guevarra RB, Kim YT, Kwon J, Kim H, Cho JH, et al. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J Microbiol Biotechnol. 2019;29(9):1335–40.PubMedCrossRef
12.
14.
go back to reference Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. Primary HIV-1 Infection is associated with preferential depletion of CD4 + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200(6):761–70.PubMedPubMedCentralCrossRef Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. Primary HIV-1 Infection is associated with preferential depletion of CD4 + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200(6):761–70.PubMedPubMedCentralCrossRef
15.
go back to reference Martens EC, Neumann M, Desai MS. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier. Nat Rev Microbiol. 2018;16(8):457–70.PubMedCrossRef Martens EC, Neumann M, Desai MS. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier. Nat Rev Microbiol. 2018;16(8):457–70.PubMedCrossRef
16.
17.
go back to reference Flygel TT, Sovershaeva E, Claassen-Weitz S, Hjerde E, Mwaikono KS, Odland J, et al. Composition of gut microbiota of children and adolescents with Perinatal Human Immunodeficiency Virus Infection taking antiretroviral therapy in Zimbabwe. J Infect Dis. 2020;221(3):483–92.PubMed Flygel TT, Sovershaeva E, Claassen-Weitz S, Hjerde E, Mwaikono KS, Odland J, et al. Composition of gut microbiota of children and adolescents with Perinatal Human Immunodeficiency Virus Infection taking antiretroviral therapy in Zimbabwe. J Infect Dis. 2020;221(3):483–92.PubMed
18.
go back to reference Pilakka-Kanthikeel PK, Kris A, Selvaraj A, Swaminathan S, Pahwa S. Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting. J Acquir Immune Defic Syndr. 2014;66(1):16–24.PubMedPubMedCentralCrossRef Pilakka-Kanthikeel PK, Kris A, Selvaraj A, Swaminathan S, Pahwa S. Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting. J Acquir Immune Defic Syndr. 2014;66(1):16–24.PubMedPubMedCentralCrossRef
19.
go back to reference Tincati C, Douek DC, Marchetti G. Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV Infection. AIDS Res Therapy. 2016;13:19.CrossRef Tincati C, Douek DC, Marchetti G. Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV Infection. AIDS Res Therapy. 2016;13:19.CrossRef
20.
go back to reference Kelly P, Davies SE, Mandanda B, Veitch A, McPhail G, Zulu I, et al. Enteropathy in zambians with HIV related Diarrhoea: regression modelling of potential determinants of mucosal damage. Gut. 1997;41(6):811–6.PubMedPubMedCentralCrossRef Kelly P, Davies SE, Mandanda B, Veitch A, McPhail G, Zulu I, et al. Enteropathy in zambians with HIV related Diarrhoea: regression modelling of potential determinants of mucosal damage. Gut. 1997;41(6):811–6.PubMedPubMedCentralCrossRef
21.
go back to reference Wang Z, Peters BA, Usyk M, Xing J, Hanna DB, Wang T et al. Gut microbiota, plasma metabolomic profiles, and carotid artery Atherosclerosis in HIV Infection. Arteriosclerosis, Thrombosis, and vascular biology. 2022;42(8):1081–93. Wang Z, Peters BA, Usyk M, Xing J, Hanna DB, Wang T et al. Gut microbiota, plasma metabolomic profiles, and carotid artery Atherosclerosis in HIV Infection. Arteriosclerosis, Thrombosis, and vascular biology. 2022;42(8):1081–93.
22.
go back to reference Ouyang J, Isnard S, Lin J, Fombuena B, Marette A, Routy B, et al. Metformin effect on gut microbiota: insights for HIV-related inflammation. AIDS Res Therapy. 2020;17(1):10.CrossRef Ouyang J, Isnard S, Lin J, Fombuena B, Marette A, Routy B, et al. Metformin effect on gut microbiota: insights for HIV-related inflammation. AIDS Res Therapy. 2020;17(1):10.CrossRef
23.
go back to reference Kang Y, Cai Y. Altered gut microbiota in HIV Infection: future perspective of fecal microbiota transplantation therapy. AIDS Res Hum Retroviruses. 2019;35(3):229–35.PubMedCrossRef Kang Y, Cai Y. Altered gut microbiota in HIV Infection: future perspective of fecal microbiota transplantation therapy. AIDS Res Hum Retroviruses. 2019;35(3):229–35.PubMedCrossRef
24.
go back to reference Zhang F, Aschenbrenner D, Yoo JY, Zuo T. The gut mycobiome in health, Disease, and clinical applications in association with the gut bacterial microbiome assembly. The Lancet Microbe. 2022;3(12):e969–e83.PubMedCrossRef Zhang F, Aschenbrenner D, Yoo JY, Zuo T. The gut mycobiome in health, Disease, and clinical applications in association with the gut bacterial microbiome assembly. The Lancet Microbe. 2022;3(12):e969–e83.PubMedCrossRef
25.
go back to reference Hiller E, Zavrel M, Hauser N, Sohn K, Burger-Kentischer A, Lemuth K, et al. Adaptation, adhesion and invasion during interaction of Candida albicans with the host–focus on the function of cell wall proteins. Int J Med Microbiology: IJMM. 2011;301(5):384–9.CrossRef Hiller E, Zavrel M, Hauser N, Sohn K, Burger-Kentischer A, Lemuth K, et al. Adaptation, adhesion and invasion during interaction of Candida albicans with the host–focus on the function of cell wall proteins. Int J Med Microbiology: IJMM. 2011;301(5):384–9.CrossRef
27.
go back to reference Logan C, Beadsworth MB, Beeching NJ. HIV and Diarrhoea: what is new? Current opinion in infectious Diseases. 2016;29(5):486–94. Logan C, Beadsworth MB, Beeching NJ. HIV and Diarrhoea: what is new? Current opinion in infectious Diseases. 2016;29(5):486–94.
28.
go back to reference Vujkovic-Cvijin I, Somsouk M. HIV and the gut microbiota: composition, consequences, and avenues for amelioration. Curr HIV/AIDS Rep. 2019;16(3):204–13.PubMedPubMedCentralCrossRef Vujkovic-Cvijin I, Somsouk M. HIV and the gut microbiota: composition, consequences, and avenues for amelioration. Curr HIV/AIDS Rep. 2019;16(3):204–13.PubMedPubMedCentralCrossRef
29.
go back to reference Zhou Y, Ou Z, Tang X, Zhou Y, Xu H, Wang X, et al. Alterations in the gut microbiota of patients with acquired immune deficiency syndrome. J Cell Mol Med. 2018;22(4):2263–71.PubMedPubMedCentralCrossRef Zhou Y, Ou Z, Tang X, Zhou Y, Xu H, Wang X, et al. Alterations in the gut microbiota of patients with acquired immune deficiency syndrome. J Cell Mol Med. 2018;22(4):2263–71.PubMedPubMedCentralCrossRef
30.
go back to reference Assimakopoulos SF, Dimitropoulou D, Marangos M, Gogos CA. Intestinal barrier dysfunction in HIV Infection: pathophysiology, clinical implications and potential therapies. Infection. 2014;42(6):951–9.PubMedCrossRef Assimakopoulos SF, Dimitropoulou D, Marangos M, Gogos CA. Intestinal barrier dysfunction in HIV Infection: pathophysiology, clinical implications and potential therapies. Infection. 2014;42(6):951–9.PubMedCrossRef
31.
go back to reference Ott SJ, Kühbacher T, Musfeldt M, Rosenstiel P, Hellmig S, Rehman A, et al. Fungi and inflammatory bowel Diseases: alterations of composition and diversity. Scand J Gastroenterol. 2008;43(7):831–41.PubMedCrossRef Ott SJ, Kühbacher T, Musfeldt M, Rosenstiel P, Hellmig S, Rehman A, et al. Fungi and inflammatory bowel Diseases: alterations of composition and diversity. Scand J Gastroenterol. 2008;43(7):831–41.PubMedCrossRef
32.
go back to reference Schaller M, Schäfer W, Korting HC, Hube B. Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol. 1998;29(2):605–15.PubMedCrossRef Schaller M, Schäfer W, Korting HC, Hube B. Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol. 1998;29(2):605–15.PubMedCrossRef
33.
go back to reference Kvaal C, Lachke SA, Srikantha T, Daniels K, McCoy J, Soll DR. Misexpression of the opaque-phase-specific gene PEP1 (SAP1) in the white phase of Candida albicans confers increased virulence in a mouse model of cutaneous Infection. Infect Immun. 1999;67(12):6652–62.PubMedPubMedCentralCrossRef Kvaal C, Lachke SA, Srikantha T, Daniels K, McCoy J, Soll DR. Misexpression of the opaque-phase-specific gene PEP1 (SAP1) in the white phase of Candida albicans confers increased virulence in a mouse model of cutaneous Infection. Infect Immun. 1999;67(12):6652–62.PubMedPubMedCentralCrossRef
34.
go back to reference Schaller M, Bein M, Korting HC, Baur S, Hamm G, Monod M, et al. The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect Immun. 2003;71(6):3227–34.PubMedPubMedCentralCrossRef Schaller M, Bein M, Korting HC, Baur S, Hamm G, Monod M, et al. The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect Immun. 2003;71(6):3227–34.PubMedPubMedCentralCrossRef
35.
go back to reference Naglik JR, Moyes D, Makwana J, Kanzaria P, Tsichlaki E, Weindl G, et al. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiol (Reading). 2008;154(Pt 11):3266–80.CrossRef Naglik JR, Moyes D, Makwana J, Kanzaria P, Tsichlaki E, Weindl G, et al. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiol (Reading). 2008;154(Pt 11):3266–80.CrossRef
36.
go back to reference Gropp K, Schild L, Schindler S, Hube B, Zipfel PF, Skerka C. The yeast Candida albicans evades human complement Attack by secretion of aspartic proteases. Mol Immunol. 2009;47(2–3):465–75.PubMedCrossRef Gropp K, Schild L, Schindler S, Hube B, Zipfel PF, Skerka C. The yeast Candida albicans evades human complement Attack by secretion of aspartic proteases. Mol Immunol. 2009;47(2–3):465–75.PubMedCrossRef
37.
go back to reference Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med. 2010;13(4):282–7.PubMed Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med. 2010;13(4):282–7.PubMed
38.
go back to reference Hamad I, Abou Abdallah R, Ravaux I, Mokhtari S, Tissot-Dupont H, Michelle C, et al. Metabarcoding analysis of eukaryotic microbiota in the gut of HIV-infected patients. PLoS ONE. 2018;13(1):e0191913.PubMedPubMedCentralCrossRef Hamad I, Abou Abdallah R, Ravaux I, Mokhtari S, Tissot-Dupont H, Michelle C, et al. Metabarcoding analysis of eukaryotic microbiota in the gut of HIV-infected patients. PLoS ONE. 2018;13(1):e0191913.PubMedPubMedCentralCrossRef
39.
go back to reference Kretschmar M, Felk A, Staib P, Schaller M, Hess D, Callapina M, et al. Individual acid aspartic proteinases (saps) 1–6 of Candida albicans are not essential for invasion and colonization of the gastrointestinal tract in mice. Microb Pathog. 2002;32(2):61–70.PubMedCrossRef Kretschmar M, Felk A, Staib P, Schaller M, Hess D, Callapina M, et al. Individual acid aspartic proteinases (saps) 1–6 of Candida albicans are not essential for invasion and colonization of the gastrointestinal tract in mice. Microb Pathog. 2002;32(2):61–70.PubMedCrossRef
40.
go back to reference Stehr F, Felk A, Kretschmar M, Schaller M, Schäfer W, Hube B. [Extracellular hydrolytic enzymes and their relevance during Candida albicans Infections]. Mycoses. 2000;43(Suppl 2):17–21.PubMed Stehr F, Felk A, Kretschmar M, Schaller M, Schäfer W, Hube B. [Extracellular hydrolytic enzymes and their relevance during Candida albicans Infections]. Mycoses. 2000;43(Suppl 2):17–21.PubMed
41.
go back to reference Banjara N, Nickerson KW, Suhr MJ, Hallen-Adams HE. Killer toxin from several food-derived Debaryomyces hansenii strains effective against pathogenic Candida yeasts. Int J Food Microbiol. 2016;222:23–9.PubMedCrossRef Banjara N, Nickerson KW, Suhr MJ, Hallen-Adams HE. Killer toxin from several food-derived Debaryomyces hansenii strains effective against pathogenic Candida yeasts. Int J Food Microbiol. 2016;222:23–9.PubMedCrossRef
42.
go back to reference Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66(6):1039–48.PubMedCrossRef Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66(6):1039–48.PubMedCrossRef
43.
go back to reference He L, Long C, Liu Y, Guo Y, Xiao N, Tan Z. Effects of Debaryomyces hansenii treatment on intestinal microorganisms in mice with antibiotics-induced diarrhea. 3 Biotech. 2017;7(5):347.PubMedPubMedCentralCrossRef He L, Long C, Liu Y, Guo Y, Xiao N, Tan Z. Effects of Debaryomyces hansenii treatment on intestinal microorganisms in mice with antibiotics-induced diarrhea. 3 Biotech. 2017;7(5):347.PubMedPubMedCentralCrossRef
44.
go back to reference Bandera A, De Benedetto I, Bozzi G, Gori A. Altered gut microbiome composition in HIV Infection: causes, effects and potential intervention. Curr Opin HIV AIDS. 2018;13(1):73–80.PubMedCrossRef Bandera A, De Benedetto I, Bozzi G, Gori A. Altered gut microbiome composition in HIV Infection: causes, effects and potential intervention. Curr Opin HIV AIDS. 2018;13(1):73–80.PubMedCrossRef
45.
go back to reference McKenna P, Hoffmann C, Minkah N, Aye PP, Lackner A, Liu Z, et al. The macaque gut microbiome in health, lentiviral Infection, and chronic enterocolitis. PLoS Pathog. 2008;4(2):e20.PubMedPubMedCentralCrossRef McKenna P, Hoffmann C, Minkah N, Aye PP, Lackner A, Liu Z, et al. The macaque gut microbiome in health, lentiviral Infection, and chronic enterocolitis. PLoS Pathog. 2008;4(2):e20.PubMedPubMedCentralCrossRef
46.
go back to reference Siddiqui U, Bini EJ, Chandarana K, Leong J, Ramsetty S, Schiliro D, et al. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol. 2007;41(5):484–90.PubMedCrossRef Siddiqui U, Bini EJ, Chandarana K, Leong J, Ramsetty S, Schiliro D, et al. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol. 2007;41(5):484–90.PubMedCrossRef
47.
go back to reference Corona A, Raimondi F. Critical care of HIV infected patients in the highly active antiretroviral therapy era. Minerva Anestesiol. 2007;73(12):635–45.PubMed Corona A, Raimondi F. Critical care of HIV infected patients in the highly active antiretroviral therapy era. Minerva Anestesiol. 2007;73(12):635–45.PubMed
Metadata
Title
Characterization of intestinal fungal community diversity in people living with HIV/AIDS (PLWHA)
Authors
Pengfei Meng
Guichun Zhang
Xiuxia Ma
Xue Ding
Xiyuan Song
Shuyuan Dang
Ruihan Yang
Liran Xu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2024
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-023-00589-x

Other articles of this Issue 1/2024

AIDS Research and Therapy 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine